Only 19.3% of the 52.9 million Americans needing substance use treatment receive it, with Medicaid-accepting facilities 3x more likely to have waitlists

Of the 52.9 million Americans aged 12+ classified as needing substance use treatment in 2024, only 19.3% (10.2 million) received any treatment in the past year. The gap is worst for young adults 18-25, where only 11.3% of those needing treatment received it. For adolescents who do seek residential treatment, only 54% of facilities had a bed immediately available, with average waitlist times of 28 days. So what: substance use disorders have a critical treatment window -- when a person is motivated to seek help, delays of even days can mean the window closes, the person relapses, and motivation evaporates. So what: a 28-day wait for a residential bed is often the difference between recovery and overdose death, particularly for opioid use disorder where relapse carries acute mortality risk. So what: 57% of Medicaid-accepting facilities report waitlists vs. 19% of non-Medicaid facilities, meaning the poorest patients face the longest waits for the most severe conditions. So what: the average cost of residential treatment is $878/day ($26,000+/month), and 48% of facilities require partial or full payment upfront, creating an impossible financial barrier for uninsured patients. So what: untreated substance use disorder drives incarceration, homelessness, child welfare involvement, and infectious disease transmission, costing society far more than treatment. The structural root cause is that the IMD exclusion in Medicaid prohibits federal matching funds for residential treatment facilities with more than 16 beds, artificially constraining facility size and capacity, while simultaneously the 'carve-out' of behavioral health from medical insurance creates separate, underfunded networks with different (lower) reimbursement standards.